235 related articles for article (PubMed ID: 28181305)
1. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
[TBL] [Abstract][Full Text] [Related]
2. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
3. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
[TBL] [Abstract][Full Text] [Related]
4. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
[TBL] [Abstract][Full Text] [Related]
5. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
6. Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Yin M; Shekiladze N; Young A; Grant A; Mahoney I; Laskar SR; Gupta D; Bhatt K; Book W; Smith A; Nguyen D; Vega JD; Morris AA
J Heart Lung Transplant; 2018 Apr; 37(4):503-512. PubMed ID: 29198929
[TBL] [Abstract][Full Text] [Related]
7. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
Yanyiam P; Kantachuvesiri S; Thammanichanond D
Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
9. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
[TBL] [Abstract][Full Text] [Related]
10. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
11. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM
Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192
[TBL] [Abstract][Full Text] [Related]
12. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
[TBL] [Abstract][Full Text] [Related]
13. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
14. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
15. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Alagusundaramoorthy S; Aziz F; Garg N; Redfield RR; Sollinger H; Kaufman D; Djamali A; Odorico J; Mandelbrot D
Transplantation; 2019 Feb; 103(2):435-440. PubMed ID: 29994978
[TBL] [Abstract][Full Text] [Related]
17. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.
Willicombe M; Brookes P; Sergeant R; Santos-Nunez E; Steggar C; Galliford J; McLean A; Cook TH; Cairns T; Roufosse C; Taube D
Transplantation; 2012 Jul; 94(2):172-7. PubMed ID: 22735711
[TBL] [Abstract][Full Text] [Related]
18. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction.
Dieplinger G; Everly MJ; Rebellato LM; Haisch CE; Briley KP; Bolin P; Kendrick WT; Kendrick SA; Morgan C; Harland RC; Terasaki PI
Transplantation; 2014 Nov; 98(10):1097-104. PubMed ID: 24911039
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
[TBL] [Abstract][Full Text] [Related]
20. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation.
McCaughan JA; Battle RK; Singh SKS; Tikkanen JM; Moayedi Y; Ross HJ; Singer LG; Keshavjee S; Tinckam KJ
Am J Transplant; 2018 Dec; 18(12):2924-2933. PubMed ID: 29847022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
